Table 1:

Demographic and clinicopathologic characteristics of women with stage I uterine serous carcinoma stratified by HER2 status

	HER2-negative n = 125	HER2-positive n = 44	p-value
Mean Age (years)	67.9 ± 8.1	68.1 ± 7.7	0.86
Median BMI (kg/m2)	32.0	28.7	0.13*
Race/Ethnicity
Caucasian/White	81 (64.8)	33 (75.0)
Black/African American	34 (27.2)	9 (20.5)
Asian	1 (0.8)	2 (4.5)
Hispanic	4 (3.2)	0 (0.0)
Other/decline to answer	5 (4.0)	0 (0.0)
ECOG† performance status			0.43
0	96 (76.8)	33 (75.0)
1	21 (16.8)	10 (22.7)
2+	8 (6.4)	1 (2.3)
History of breast cancer	22 (17.6)	4 (9.1)	0.23‡
Surgical approach
Minimally invasive (including robotic)	66 (52.8)	24 (54.6)	0.84
Laparotomy	59 (47.2)	20 (45.4)
Omentectomy	94 (75.2)	34 (77.3)	0.78
Pelvic lymphadenectomy	114 (91.2)	43 (97.7)	0.15
Pelvic and para-aortic lymphadenectomy	102 (81.6)	35 (79.6)	0.77
Pelvic washings	102 (81.6)	38 (86.4)	0.47
Stage (FIGO 2009)
IA	100 (80.0)	31 (70.4)	0.19
IB	25 (20.0)	13 (29.6)
Originating in polyp	45 (36.0)	17 (38.6)	0.76
Histology
Pure serous	107 (85.6)	33 (75.0)	0.27
Mixed serous-endometrioid	15 (12.0)	9 (20.4)
Mixed serous-clear cell	3 (2.4)	2 (4.6)
Myometrial invasion	75 (60.0)	30 (68.2)	0.34
Lymph-vascular space invasion	23 (18.4)	18 (40.9)	0.003
Positive peritoneal cytology (n=140)	9 (8.8)	3 (7.9)	1.00 ‡
Adjuvant therapy
None	31 (24.8)	11 (25.0)	0.99
Vaginal brachytherapy alone	6 (4.8)	2 (4.6)
Chemotherapy alone	34 (27.2)	11 (25.0)
Combined chemo-radiotherapy**	54 (43.2)	20 (45.4)
Median follow-up (months)	52 (22–95)	43 (19–80)	0.26*

Data are mean ± SD, median (interquartile range), or n (%)

^*p-value determined using Wilcoxon rank-sum test

^†ECOG = Eastern Cooperative Oncology Group

^‡p-value determined using Fisher’s exact test

^**61 patients received brachytherapy, 6 patients pelvic radiotherapy, 7 patients brachytherapy + pelvic radiotherapy